The Latest Biotech Industry Statistics Explained
The global biotechnology market size was valued at USD 484.5 billion in 2019.
The statistic indicates that the global biotechnology market was estimated to be worth $484.5 billion in the year 2019. This value represents the total revenue generated by the biotechnology industry worldwide from various products and services related to biotechnology research, development, and production. The market size reflects the scale and economic significance of the biotechnology sector, encompassing diverse areas such as pharmaceuticals, agriculture, energy, and environmental applications. The figure underscores the substantial investment and activity in biotechnology, highlighting its role in driving innovation, addressing societal needs, and contributing to economic growth on a global scale.
The biotechnology industry is projected to reach USD 729.7 billion by 2025, growing at a CAGR of 7.4% from 2020-2025.
This statistic indicates that the biotechnology industry is expected to experience robust growth over the forecasting period from 2020 to 2025, with a compound annual growth rate (CAGR) of 7.4%. The projected market size of USD 729.7 billion by 2025 signifies a significant expansion from the base year of 2020. This growth trajectory suggests a positive outlook for the biotechnology sector, driven by factors such as advancements in technology, increased funding for research and development, and rising demand for innovative healthcare solutions. The CAGR provides a measure of the industry’s steady growth rate over the years, highlighting the potential for continued expansion and opportunity within the biotechnology market.
The United States has the largest biotech industry, with over 47% of the global total in revenues.
The statistic indicates that the United States dominates the global biotech industry, contributing to over 47% of the total revenues generated in this sector worldwide. This suggests that the United States is a key player in the field of biotechnology, leading in innovation, research, and commercialization of biotech products and services. The substantial revenue share also reflects the country’s significant investment in biotech research and development, as well as its strong infrastructure and supportive regulatory environment for biotech companies. Overall, the statistic highlights the United States’ prominent position in the global biotech landscape, symbolizing its leadership and competitiveness in this crucial and rapidly growing industry.
The U.S. biotech sector had an annual revenue of around $112 billion in 2018.
The statistic stating that the U.S. biotech sector generated an annual revenue of approximately $112 billion in 2018 provides insight into the economic importance and growth of this industry within the United States. This figure demonstrates the significant financial impact of biotechnology firms operating in the country, reflecting the sector’s substantial contribution to the overall economy. The revenue generated by the biotech sector in 2018 highlights the sector’s strength and potential for innovation, research, and development of biopharmaceuticals, medical devices, agricultural products, and other biotechnology-related products and services. This statistic underscores the importance of the biotech industry in driving economic growth, creating jobs, and advancing scientific discoveries within the United States.
There are over 3,000 biotechnology firms in the United States alone.
The statistic stating that there are over 3,000 biotechnology firms in the United States alone highlights the significant presence and impact of the biotechnology industry in the country. This large number of firms indicates a thriving and competitive landscape within the biotechnology sector, with a diverse array of companies conducting research, development, and commercialization of biotechnological innovations. The presence of numerous biotechnology firms also suggests significant investment in research and development within the industry, as well as potential opportunities for economic growth, job creation, and technological advancements in areas such as healthcare, agriculture, and environmental sustainability within the United States.
As of 2020, the U.S. biotech industry accounted for approximately 2.92% of the U.S. GDP.
The statistic indicates that in the year 2020, the biotech industry in the United States contributed around 2.92% to the country’s Gross Domestic Product (GDP). This suggests that the biotech sector played a significant role in the overall economic activity of the U.S. during that year. Biotechnology encompasses a wide range of activities, including research and development, production, and commercialization of products in areas such as pharmaceuticals, agriculture, and healthcare. The fact that the industry accounted for nearly 3% of the GDP highlights its importance as a key driver of economic growth and innovation in the U.S. economy.
Over 60% of the biotech industry is made up of firms with fewer than 50 employees.
The statistic indicates that a significant majority of companies within the biotech industry are classified as small businesses, as they have fewer than 50 employees. This distribution suggests that the biotech industry is largely composed of small and medium-sized enterprises (SMEs) rather than large corporations. These smaller firms play a crucial role in driving innovation and competitiveness within the industry, as they often focus on niche markets, novel technologies, and specialized research. The prevalence of small biotech companies highlights the dynamic and diverse nature of the industry, with a wide range of players contributing to the overall growth and development of biotechnology.
As of 2020, approximately 16.5% of biotech investing goes into oncology-related projects.
The statistic states that as of 2020, around 16.5% of the total investment in the biotechnology sector is directed towards projects related to oncology, which is the study and treatment of cancer. This suggests a significant emphasis on developing new technologies, drugs, and therapies aimed at combating cancer within the biotech industry. The allocation of a substantial portion of funding towards oncology projects indicates the high priority placed on addressing the challenges and opportunities present in the field of cancer research and treatment, reflecting the ongoing initiatives and advancements in the fight against cancer within the biotechnology sector.
The biotech IPO market raised $10.7 billion across 86 launches in 2020, nearly triple the 2019 total.
The statistic indicates that the biotech Initial Public Offering (IPO) market had a remarkably successful year in 2020, with $10.7 billion raised through 86 launches. This represents a significant increase compared to the previous year, nearly tripling the total amount raised in 2019. The substantial growth in funding raised suggests a strong investor interest in the biotech sector, likely driven by factors such as the COVID-19 pandemic highlighting the importance of healthcare and biotechnological advancements. The surge in biotech IPOs and funding in 2020 highlights the sector’s resilience and potential for innovation and growth amidst turbulent market conditions.
40% of all the biotech firms in the world are located in the US.
The statistic “40% of all the biotech firms in the world are located in the US” indicates that a substantial proportion of biotechnology companies globally are situated in the United States. This suggests that the US is a dominant player in the biotech industry, likely due to factors such as strong research and development capabilities, a supportive regulatory environment, access to capital markets, and a well-established network of universities and research institutions. The concentration of biotech firms in the US implies that the country is a key hub for innovation, investment, and collaboration in the field of biotechnology, shaping its position as a leader in the global biotech market.
As of 2019, there were 13,885 biotech patents granted in the United States.
The statistic “As of 2019, there were 13,885 biotech patents granted in the United States” indicates that in the year 2019, a total of 13,885 patents related to biotechnology were granted by the United States Patent and Trademark Office (USPTO). This could suggest a significant level of innovation and research activity within the biotechnology industry in the United States during that year. Biotech patents are important as they represent intellectual property protection for novel inventions and discoveries in areas such as genomics, drug development, and medical devices, which can spur economic growth and technological advancement in the biotech sector. Understanding the number of granted patents can also provide insights into the level of competitiveness and innovation within the industry at a given point in time.
In Europe there are over 2,600 dedicated biotechnology firms.
The statistic that there are over 2,600 dedicated biotechnology firms in Europe signifies a robust and flourishing biotechnology industry in the region. This large number of firms highlights the significant investment, innovation, and expertise present in the European biotechnology sector. These firms are likely engaged in a wide range of activities, including pharmaceuticals, agriculture, and healthcare, contributing to advancements in medicine, agriculture, and environmental sustainability. The presence of so many biotechnology firms points to a competitive landscape in Europe, with ample opportunities for collaboration, growth, and technological advancements within the industry.
The European biotech industry grew by 5% annually from 2012 to 2017.
The statistic that the European biotech industry grew by 5% annually from 2012 to 2017 indicates a consistent and positive trend in the industry’s expansion over that period. The 5% annual growth rate suggests that the industry was able to sustainably increase its output, revenue, or other relevant metrics by that percentage each year. This steady growth signifies a healthy and thriving biotech sector in Europe during those years, reflecting favorable market conditions, technological advancements, and innovation within the industry. The statistic underscores the industry’s resilience and potential for further development in the future.
Asian countries, excluding Japan, accounted for just 14% of the global biotech revenue in 2016.
This statistic indicates that Asian countries, excluding Japan, collectively generated only 14% of the total global biotech revenue in 2016. This suggests that biotechnology industries in Asian countries, apart from Japan, have not yet reached a significant level of revenue generation compared to other regions in the world. It may imply that there is a potential for growth and development in the biotech sector in these Asian countries, as they currently represent a relatively small share of the global market. This statistic could also highlight areas for improvement and increased investment in research, development, and innovation within the biotechnology industries of these Asian countries to enhance their competitiveness and contribution to the global biotech market.
Chinese biotech firms raised over $7.6 billion in 2021, a significant increase from previous years.
The statistic indicates that in 2021, Chinese biotech firms collectively secured a total investment amount exceeding $7.6 billion, representing a substantial rise compared to the funding levels seen in previous years. This suggests a growing investor confidence in the Chinese biotech sector, possibly driven by advancements in technology and innovation within the industry, as well as an expanding market demand for biotech products and services. The significant increase in funding points towards a positive trajectory for the Chinese biotech sector, showcasing its potential for further growth, development, and impact both domestically and globally.
Regulation-related delays in European Union cost biotech crop industry $20 billion annually.
The statistic indicates that regulatory processes and delays in the European Union have resulted in significant financial losses for the biotech crop industry, amounting to $20 billion annually. These delays could stem from lengthy approval procedures, strict regulations, or other barriers that hinder the commercialization and adoption of biotech crops within the European market. The substantial financial impact highlights the importance of efficient and transparent regulatory frameworks to enable innovation and growth in the biotech industry. This statistic underscores the need for policymakers to consider the balance between ensuring consumer and environmental safety while also fostering a competitive and sustainable agricultural sector.
In the biotechnology industry, medical/health makes up the largest segment with a 61.3% market share.
The statistic indicates that within the biotechnology industry, the medical/health sector holds the largest market share at 61.3%. This means that a significant portion of the biotechnology industry’s activities and revenues are focused on developing products and technologies related to healthcare and medicine. Companies within this segment are likely to be involved in research, development, and commercialization of pharmaceuticals, medical devices, diagnostics, and other healthcare-related innovations. The dominance of the medical/health segment suggests that there is a strong emphasis on addressing medical needs and advancing healthcare solutions within the biotechnology industry. Additionally, this statistic highlights the importance of the medical/health sector in driving growth and innovation within the broader biotechnology landscape.
By 2025, Cancer Biotherapeutics is expected to drive the biotech industry with a projected value of $87 billion.
The statistic indicates that Cancer Biotherapeutics is forecasted to be a significant driver of growth within the biotech industry by the year 2025, with a projected value of $87 billion. This suggests that cancer-focused biotechnology products and treatments, such as immunotherapies and targeted therapies, are expected to play a key role in shaping the industry landscape and driving revenue in the near future. The substantial projected value highlights the increasing importance and potential profitability of cancer biotherapeutics within the biotech sector, indicating a growing demand for innovative treatments targeting cancer and related diseases. As such, stakeholders in the biotech industry are likely to focus on investing in research and development in this area to capitalize on the potential growth opportunities presented by cancer biotherapeutics.
Over 1.72 million jobs, both direct and indirect, were supported by the U.S. biopharma sector as of 2014.
The statistic states that as of 2014, the U.S. biopharma sector was responsible for supporting over 1.72 million jobs, which includes both direct employment within the sector itself and indirect employment in related industries. This indicates the significant economic impact and level of employment generated by the biopharma sector in the United States. The biopharma sector encompasses various activities related to the development, manufacturing, and distribution of pharmaceuticals and biotechnology products, contributing to job creation not only within the sector but also in supporting industries such as research, healthcare, and logistics. Overall, this statistic underscores the importance of the biopharma sector as a key driver of employment and economic growth in the U.S. economy.
References
0. – https://www.www.mordorintelligence.com
1. – https://www.www.statista.com
2. – https://www.www.nature.com
3. – https://www.www.ey.com
4. – https://www.www.bio.org
5. – https://www.www.biostimulants.eu
6. – https://www.www.evaluate.com
7. – https://www.www.grandviewresearch.com
8. – https://www.www.selectusa.gov
9. – https://www.croplife.org
10. – https://www.www.ibisworld.com
11. – https://www.www.bioworld.com
